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We examined the association of reproductive and hormonal factors with renal cell cancer risk in a cohort study of 89835 Canadian
women. Compared with nulliparous women, parous women were at increased risk (hazard ratio (HR) 1.78, 95% confidence interval
(CI) 1.02–3.09), and there was a significant gradient of risk with increasing levels of parity: relative to nulliparous women, women who
had X5 pregnancies lasting 4 months or more had a 2.4-fold risk (HR¼2.41, 95% CI¼1.27–4.59, P for trend 0.01). Ever use of oral
contraceptives was associated with a modest reduction in risk. No associations were observed for age at first live birth or use of
hormone replacement therapy. The present study provides evidence that high parity may be associated with increased risk of renal
cell cancer, and that oral contraceptive use may be associated with reduced risk.
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Incidence rates of renal cell cancer have been increasing both in
the USA and globally since the 1970s (Chow et al, 1999;
McLaughlin et al, 2006), and renal cell carcinomas account for
approximately 80% of renal cancers (McLaughlin et al, 2006).
While cigarette smoking, obesity, and hypertension are established
risk factors for renal cell cancer, few other risk factors have been
identified conclusively (Lindblad and Adami, 2002; McLaughlin
et al, 2006). Smoking, obesity, and hypertension have been
estimated to account for roughly 68% of renal cancer incidence
in women (Benichou et al, 1998), leaving a substantial proportion
of this cancer still unexplained.
A number of findings suggest a possible role of reproductive or
hormonal factors in renal cell cancer. First, over the past 30 years,
incidence rates of renal cell cancer have been increasing more
rapidly in women than in men in the USA and the UK (Katz et al,
1994; Chow et al, 1999; Tate et al, 2003), suggesting a possible
association with exposure to exogenous hormones. Second, steroid
hormone receptors have been found in both normal and cancerous
renal cell tissue, suggesting hormonal regulation (Ronchi et al,
1984; Siiteri, 1987; Vugrin, 1987). Third, renal tumours can be
induced in experimental animals with diethylstilbestrol and
oestradiol (Kirkman, 1959; Reznik-Schuller, 1979; Li and Li,
1990). Finally, obesity, a consistent risk factor for renal cell
cancer, is the main source of endogenous exposure to oestrogen in
postmenopausal women (Siiteri, 1987).
Only a few studies have examined endocrine factors in relation
to renal cell cancer risk (Krieger et al, 1992; McCredie and Stewart,
1992; Cantor et al, 1993; Mellemgaard et al, 1994; Chow et al, 1995;
Lindblad et al, 1995; Gago-Dominguez et al, 1999; McLaughlin and
Lipworth, 2000; Lambe et al, 2002; Nicodemus et al, 2004) and
their findings have been inconsistent. Only two cohort studies
(Lambe et al, 2002; Nicodemus et al, 2004) have addressed the role
of reproductive and hormonal factors, but each was limited to two
exposures of interest. Given the current lack of data from
prospective studies on this topic, we examined the association
between reproductive and hormonal factors and renal cell cancer
risk in a cohort of Canadian women.
MATERIALS AND METHODS
Study population
The study, which has been described in detail elsewhere (Miller
et al, 1992), was conducted among participants in the Canadian
National Breast Screening Study (NBSS), a randomised controlled
trial of screening for breast cancer. A total of 89835 women aged
40–59 years with no history of breast cancer were recruited into
the trial between 1980 and 1985. Participating women were
randomised to receive either (1) screening with annual mammo-
graphy, breast physical examination, and instruction on breast
self-examination on four or five occasions, or (2) community care
after a single breast physical examination and instruction on breast
self-examination. The NBSS was approved by the appropriate
Institutional Review Boards, and informed consent was obtained
from all study participants.
Questionnaires and anthropometric measurements
At recruitment into the cohort, participants completed self-
administered questionnaires that sought information on demo-
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ing), menstrual and reproductive history, and use of oral contra-
ceptives and hormone replacement therapy (HRT). Specifically,
participants were asked questions about their age at menarche,
menopausal status, number of pregnancies lasting greater than 4
months (parity), age at first live birth, and ever use and duration of
use of oral contraceptives and of HRT. In addition, height and
weight were measured at the initial physical examination.
Ascertainment of incident renal cell cancer cases and
deaths
Incident cases of renal cell cancer and deaths from all causes were
ascertained, respectively, by means of computerised record
linkages to the Canadian Cancer Database and to the National
Mortality Database, both of which are maintained by Statistics
Canada. The linkages to the databases yielded data on cancer
incidence and mortality to 31 December 2000 for women in
Ontario, 31 December 1998 for women in Quebec, and 31
December 1999 for women in other provinces.
Statistical analysis
Of the 89835 women recruited into the study, we excluded women
with prevalent renal cancer at baseline (n¼14), leaving 89821
women available for analysis, among whom 199 incident cases of
renal cancer were observed. We further excluded 27 cases with
cancer of the renal pelvis and a morphology code of transitional
cell carcinoma, leaving 172 cases with cancer of the renal
parenchyma. For these analyses, study participants were consid-
ered at risk from their date of enrolment until the date of diagnosis
of their renal cell carcinoma, termination of follow-up (the date to
which cancer incidence data were available for women in the
corresponding province) or death, whichever occurred first. Cox
proportional hazards models (using age as the time scale) were
used to estimate hazard ratios (HRs) and 95% confidence intervals
(CIs) for the association between reproductive and hormonal
factors and renal cell cancer risk. All multivariate models included
terms for body mass index (BMI) (kgm
 2) (quintiles), pack-years
of smoking (never smokersþfive levels), menopausal status at
baseline (pre-, peri-, postmenopausal), education (three levels),
study centre, and randomisation group (intervention or control in
the original clinical trial). Women who reported having regular
menstrual periods within the 12 months before baseline or who
had had a hysterectomy without bilateral oophorectomy and were
less than 45 years of age were classified as premenopausal. Women
whose menstrual periods ceased more than 12 months before
baseline, those who had had a bilateral oophorectomy, and those
who had had a hysterectomy and were over 55 years of age were
considered postmenopausal (Rohan et al, 1998). Women whose
periods were irregular and those who had a hysterectomy and were
between 45 and 55 years old were considered perimenopausal. To
test for trends in risk with increasing levels of the exposures of
interest, we either assigned the categorical variables (parity) their
ordinal number or the category median (age at first live birth,
duration of oral contraceptive use, duration of HRT) and then
fitted the assigned value of each risk factor as a continuous
variable in the risk models. We then evaluated the statistical
significance of the corresponding coefficient using the Wald test
(Rothman and Greenland, 1998). Tests for interaction were based
on comparing the likelihood ratio tests in models with and without
the product terms representing the variables of interest. The
likelihood ratio test that all of the interaction parameters were 0
was performed by referring 2* the absolute difference in the log
likelihoods of models with and without interaction terms to the w
2
distribution with degrees of freedom equal to the number of
interaction parameters. Use of the life-test procedure in SASt
showed that the proportional hazards assumption was met in this
data set. All analyses were performed using SAS version 9 (SAS
Institute Cary, NC, USA).
RESULTS
The average duration of follow-up for cohort members was 16. 4
years (1474006 person-years). Table 1 shows the baseline
characteristics of the study population by case status at the end
of follow-up. Briefly, compared to non-cases, renal cell cancer
cases were older, had a higher mean BMI, were more likely to have
had five or more pregnancies lasting greater than 4 months, were
more likely to be postmenopausal, were more likely to be current
smokers, and were less likely to have ever used oral contraceptives.
Compared to nulliparous women, parous women had an
increased risk of renal cell cancer (multivariate-adjusted HR
1.78, 95% CI 1.02–3.09), and there was a significant gradient with
increasing level of parity: relative to nulliparous women, women
who had X5 pregnancies lasting 4þ months had a 2.4-fold risk
(HR¼2.41, 95% CI¼1.27–4.59, P for trend¼0.01) (Table 2). A
relatively late age at menarche appeared to be associated with a
modestly increased risk, and ever use of oral contraceptives was
associated with slightly reduced risk. However, these results did
not achieve statistical significance, and there was no clear trend
with age at menarche or duration of oral contraceptive use.
Perimenopausal and postmenopausal women were at increased
risk compared to premenopausal women. No associations were
seen with age at first live birth or use of HRT.
Both smoking and BMI showed positive dose–response
relationships, in line with previous studies. Compared to never
smokers, smokers of 40þ pack-years had a HR of 2.12, 95% CI
1.21–3.71, P for trend 0.004; compared to the lowest quintile of
BMI, women in the highest quintile had a HR of 1.76, 95% CI 1.03–
3.03, P for trend 0.02. Table 3 presents the associations of parity
and oral contraceptive use stratified by major known risk factors.
The positive association of parity with renal cell cancer was limited
to women 50–59 years old at enrolment (P for interaction¼0.11)
and to never smokers (P for interaction o0.005). For women aged
Table 1 Baseline characteristics of the study population by outcome
Factor
Incident renal cell
cancer cases
(n¼172)
Non-cases
(n¼89617)
Mean age at baseline
(years)
50.7 (5.6) 48.5 (5.6)
Mean BMI (kgm
 2)
a 26.1 (5.1) 25.1 (4.7)
Mean age at menarche
(years)
13.0 (1.4) 12.8 (2.2)
Mean age at first live
birth (years)
b
23.7 (3.7) 24.2 (4.8)
Parity (%)
Nulliparous 9.3 14.4
1–2 32.0 35.5
3–4 40.1 38.4
5+ 18.6 11.7
Postmenopausal (%) 44.2 37.0
Cigarette smoking (%)
Never smoked 44.8 52.2
Former smoker 25.0 26.0
Current smoker 30.2 21.8
HRT use (% ever)
c 46.1 47.0
Oral contraceptives use
(% ever)
51.7 58.1
aBMI¼body mass index.
bAmong parous women only.
cHRT¼hormone replace-
ment therapy; results among postmenopausal women only.
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pregnancies lasting 4þ months was 3.43, 95% CI 1.40–8.43, P for
trend 0.009, and a HR of 3.72, 95% CI 1.35–10.24, P for trend
0.0006 was observed among never smokers. The association of
parity with renal cell cancer did not differ by the level of BMI. The
inverse association of oral contraceptive use with renal cell cancer
was more pronounced among never smokers: HR 0.55, 95% CI
0.34–0.88 (P for interaction 0.01). There was also a suggestion that
the associations for oral contraceptive use were stronger in
younger women (40–49 years old) and overweight women
(BMIX25.1kgm
 2).
DISCUSSION
In the prospective study reported here, we found a statistically
significant increased risk of renal cell cancer in women with
increasing parity, which was comparable in strength to the
associations with smoking and BMI. The association with parity
was strongest in women who were older at enrolment and in never
smokers. There was a suggestion of reduced risk with a relatively
early age at menarche and with ever use of oral contraceptives, but
these associations did not achieve statistical significance. Renal cell
cancer risk was not associated with age at first live birth or use of
HRT. Both smoking and BMI showed positive dose–response
relationships with renal cancer risk in this cohort, in line with
previous studies.
Most previous studies have examined only a limited number of
reproductive factors, most commonly parity and age at first live
birth. Of nine studies that provided data on parity, four found no
association (Krieger et al, 1992; McCredie and Stewart, 1992;
Mellemgaard et al, 1994; Gago-Dominguez et al, 1999), one showed
a borderline positive association (Cantor et al, 1993), and four
(including the two cohort studies) showed a significant positive
association (Chow et al, 1995; Lindblad et al, 1995; Lambe et al,
2002; Nicodemus et al, 2004). Similar to these latter studies, we
Table 2 Age-adjusted and multivariate-adjusted hazard ratios (HR) and 95% confidence intervals (95% CI) for the association between lifestyle,
reproductive, and hormonal factors and risk of incident renal cell cancer
Factor Cases/person years Age-adjusted HR
a (95% CI) Multivariate HR
b (95% CI)
Parity
Nulliparous 16/212504 1.00 (reference) 1.00 (reference)
Parous 156/1261502 1.63 (0.97–2.72) 1.78 (1.02–3.09)
1–2 55/522816 1.40 (0.80–2.44) 1.62 (0.90–2.92)
3–4 69/567220 1.61 (0.93–2.78) 1.77 (0.99–3.16)
5+ 32/171465 2.48 (1.36–4.53) 2.41 (1.27–4.59)
P for trend 0.002 0.01
Age at first live birth (years)
c
o20 23/212504 1.00 (reference) 1.00 (reference)
20–22 40/469625 1.77 (1.02–3.07) 0.88 (0.52–1.48)
23–25 46/360111 1.68 (0.95–2.97) 1.00 (0.59–1.69)
26–29 37/273117 1.79 (1.00–3.22) 1.09 (0.63–1.90)
30+ 10/151912 0.87 (0.40–1.93) 0.54 (0.25–1.17)
P for trend 0.97 0.45
Age at menarche (years)
o12 25/257779 1.00 (reference) 1.00 (reference)
12 39/341764 1.19 (0.72–1.96) 1.21 (0.73–2.00)
13 52/429850 1.25 (0.78–2.02) 1.33 (0.82–2.15)
14+ 56/445932 1.32 (0.83–2.12) 1.37 (0.85–2.20)
P for trend 0.25 0.20
Menopausal status
Pre- 61/725258 1.00 (reference) 1.00 (reference)
Peri- 35/209540 1.98 (1.30–3.01) 1.74 (1.12–2.71)
Post- 76/539649 1.67 (1.19–2.34) 1.47 (1.00–2.16)
Oral contraceptives
Never 83/611469 1.00 (reference) 1.00 (reference)
Ever 89/863819 0.75 (0.56–1.02) 0.80 (0.58–1.09)
1–11 months 19/170748 0.82 (0.50–1.35) 0.81 (0.48–1.35)
12–35 months 21/194388 0.80 (0.49–1.29) 0.86 (0.53–1.40)
36–95 months 29/298430 0.71 (0.47–1.09) 0.75 (0.49–1.17)
96+ months 29/200252 0.73 (0.45–1.20) 0.80 (0.48–1.31)
P for trend 0.08 0.20
HRT use
d
Never 122/1102965 1.00 (reference) 1.00 (reference)
Ever 50/372361 1.24 (0.89–1.72) 0.98 (0.69–1.41)
1–12 months 18/118416 1.39 (0.85–2.28) 1.02 (0.56–1.85)
13–59 months 12/106984 1.04 (0.57–1.87) 0.98 (0.53–1.82)
60+ months 13/104848 1.32 (0.80–2.17) 0.91 (0.51–1.63)
P for trend 0.25 0.74
aAdjusted for age (time to event variable).
bAdjusted for age (time to event variable), pack-years (never smokers + five levels), body mass index (quintiles), menopausal status
(pre-, peri-, postmenopausal), education (three levels), study centre, randomisation group (intervention vs control), and the other variables in the table.
cParous women only.
dPostmenopausal women only.
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increasing parity.
Findings regarding an association of age at first live birth have
been weaker and less consistent. Two case–control studies
indicated no association of age at first live birth with renal cell
cancer (Cantor et al, 1993; Lindblad et al, 1995), whereas two other
case–control studies suggested a borderline inverse association
(Mellemgaard et al, 1994; Chow et al, 1995). The large cohort study
by Lambe et al (2002) reported a significant inverse association,
the OR in the highest quartile relative to that in the lowest being
0.89 (95% CI 0.69–1.15), P for trend 0.04, suggesting, at most, an
association of relatively small magnitude. We found no clear
evidence of a trend with age at first live birth, and the 40%
reduction in risk among women who had their first live birth at 30
years or greater was based on only 10 cases.
Of the four studies (all case–control) presenting findings on age
at menarche, two (McCredie and Stewart, 1992; Chow et al, 1995)
showed no association, whereas the other two suggested that risk
decreases with increasing age at menarche (Mellemgaard et al,
1994; Lindblad et al, 1995); however, neither the individual risk
estimates nor the trends approached statistical significance. We
found a nonsignificant increased risk with older age at menarche,
although the trend was not statistically significant. Analysis of the
large case–control study by Lindblad et al (1995) showed that,
after careful adjustment for BMI, parity, and other factors, the
inverse associations with age at first birth and age at menarche
were attenuated.
Of four studies of oral contraceptive use (Mellemgaard et al,
1994; Chow et al, 1995; Lindblad et al, 1995; Gago-Dominguez et al,
1999), three showed some evidence of reduced risk among users,
the other finding no association (Gago-Dominguez et al, 1999).
Our results are suggestive of a 20% reduction in risk among ever
users of oral contraceptives, although there was no trend with
duration of use. In the analysis stratified by age at enrolment, a
greater reduction in risk was seen in younger women. Findings
concerning hormone replacement use have been inconsistent
(Mellemgaard et al, 1994; Chow et al, 1995; Lindblad et al, 1995;
Gago-Dominguez et al, 1999; Nicodemus et al, 2004). In keeping
with two case–control studies (Lindblad et al, 1995; Gago-
Dominguez et al, 1999), we found no evidence of an association
with ever use or with duration of use.
Whereas smoking, obesity, and hypertension are established
risk factors for renal cell cancer (Lindblad and Adami, 2002;
McLaughlin et al, 2006), it is unclear whether reproductive or
hormonal factors play a role. A number of findings support the
concept that pregnancy-associated hormonal changes, and,
particularly, high oestrogen levels, may promote malignant
changes by stimulating renal cell proliferation either directly or
via growth factors (Concolino et al, 1993). These findings include
the fact that administration of potent oestrogens has been shown
to induce renal cancers in the Syrian hamster (Kirkman, 1959;
Reznik-Schuller, 1979; Li and Li, 1990; Cavalieri et al, 2001), the
presence of oestrogen and progesterone receptors in normal and
malignant renal cells (Concolino et al, 1976; Ronchi et al, 1984),
and the observed association with obesity, which provides a major
source of oestrogen in postmenopausal women. However, the
evidence supporting a role of exposure to endogenous or
exogenous oestrogens in renal cell carcinogenesis is conflicting.
The association of factors such as age at menarche, age at
menopause, parity, and exogenous oestrogen exposure with renal
cell cancer presents a markedly different pattern from that seen for
breast and endometrial cancer. The male predominance in
incidence rates of the disease, the positive association with parity
in some studies, and the observed reduction in risk in users of
oral contraceptives in some studies suggest that exposure to endo-
genous oestrogens may be protective rather than a risk factor.
Furthermore, the appropriateness of the Syrian hamster animal
model to renal cell carcinoma in humans has been questioned
(Gago-Dominguez et al, 2002).
The positive association with parity may reflect the association
of normal pregnancies with hyperfiltration (Krutzen et al, 1992;
Sturgiss et al, 1996). Based on animal studies, glomerular
hyperfiltration may play a role in the development of glomerulo-
sclerosis (Neuringer and Brenner, 1992; Westenend et al, 1992),
which makes the nephrons more susceptible to exposure to
carcinogens. Furthermore, pregnancy-associated weight gain could
provide a partial explanation for the association of parity with
renal cell cancer (Lambe et al, 2002).
Recently, an attempt has been made to provide a unified
explanation of the aetiology of renal cell cancer based on the
mechanism of lipid peroxidation (Gago-Dominguez et al, 2002).
Gago-Dominguez et al noted that lipid peroxidation is increased
among both obese and hypertensive subjects, and that in animal
models lipid peroxidation of the proximal renal tubules has been
shown to be a necessary condition for chemically induced renal
carcinogenesis. The authors argued that lipid peroxidation may
also explain the association of other risk factors, including
cigarette smoking, the male preponderance of kidney cancer,
parity, diabetes, and a protective effect of antioxidants, as there is
evidence indicating that these risk factors are associated with
increased lipid peroxidation, and that dietary antioxidants are
Table 3 Multivariate-adjusted hazard ratios (HR) and 95% confidence
intervals (95% CI) for the association between parity and oral contraceptive
use and renal cell cancer, stratified by other risk factors
Stratification variables
HR
a
(95% CI)
HR
a
(95% CI)
P for
interaction
Age at enrolment 40–49 years 50–59 years
Parity
Nulliparous 1.00 (reference) 1.00 (reference)
1–2 1.05 (0.90–1.28) 2.21 (0.92–5.33)
3–4 1.15 (0.53–2.48) 2.28 (0.96–5.41)
5+ 0.97 (0.32–2.96) 3.43 (1.40–8.43) 0.11
P trend 0.86 0.009
Oral contraceptive use
Never 1.00 (reference) 1.00 (reference)
Ever 0.77 (0.46–1.29) 0.90 (0.61–1.34) 0.35
Smoking status Never smokers Ever smokers
Parity
Nulliparous 1.00 (reference) 1.00 (reference)
1–2 1.40 (0.51–3.84) 1.46 (0.73–2.95)
3–4 2.71 (1.06–6.97) 1.10 (0.53–2.27)
5+ 3.72 (1.35–10.24) 1.65 (0.72–3.78) o0.005
P for trend 0.0006 0.67
Oral contraceptive use
Never 1.00 (reference) 1.00 (reference)
Ever 0.55 (0.34–0.88) 0.97 (0.64–1.49) 0.01
Body mass index o25.1kgm
 2 425.1kgm
 2
Parity
Nulliparous 1.00 (reference) 1.00 (reference)
1–2 1.34 (0.63–2.86) 1.45 (0.71–3.65)
3–4 1.47 (0.70–3.11) 1.61 (0.71–3.65)
5+ 2.07 (0.86–5.01) 2.13 (0.88–5.11) 0.48
P for trend 0.12 0.09
Oral contraceptive use
Never 1.00 (reference) 1.00 (reference)
Ever 0.87 (0.55–1.37) 0.77 (0.50–1.19) 0.63
aAdjusted for age (time to event variable), menopausal status (pre-, peri-,
postmenopausal), education (three levels), study centre, randomisation group
(intervention vs control), and the other variables in the table apart from those
involved in a particular interaction.
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pregnant women have been observed to have higher levels of
serum lipid peroxide compared to nonpregnant women (Gago-
Dominguez et al, 2002). Gago-Dominguez et al (2002) further
point to Fe-NTA-induced renal carcinogenesis in rats and mice as
providing an experimental model relevant to human renal cell
cancer. Intraperitoneal injections of Fe-NTA in rodents induce
necrosis of the proximal renal tubules and, subsequently, a high
incidence (60–92%) of renal cell carcinoma. This model appears to
correspond to human renal cell carcinoma, given that the tumour
incidence in male rats is twice as high as in female rats, and that
the histology involves clear and granular cells.
Strengths of the present study include its prospective nature, the
availability of information on a number of reproductive and
hormonal factors as well as other risk factors, and the high level of
follow-up over a period of 16 years. A number of limitations
should also be noted. First, information was not available on
several factors of interest, including history of hypertension,
miscarriages and abortions, and the specific regimen of HRT.
Second, only information collected at baseline was available, so
that we were not able to take into account changes in the exposures
of interest over the follow-up period. Nevertheless, we were able to
detect monotonic dose–response relationships with smoking and
BMI, and our results regarding parity and oral contraceptive use
are in agreement with the findings of the larger previous studies. It
is unclear, however, whether changes in parity or in oral
contraceptive use have contributed to the increasing rates of renal
cell carcinoma in women.
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